OR WAIT null SECS
December 19, 2025
Article
The approval is based on phase 3 SEQUOIA-HCM clinical trial. The full US Prescribing Information includes a Boxed Warning for the risk of heart failure.
December 04, 2025
Catch up with major FDA decisions, critical conference news, and more.
December 03, 2025
Video
Bilen discusses the COLLIGO-HCM trial, investigating the real-world efficacy of mavacamten monotherapy for patients with obstructive HCM.
November 28, 2025
Yan discusses the reversion of 50-year trends in mortality and the steps needed to reduce these rates back to pre-pandemic levels.
November 14, 2025
Acoramidis also increased serum transthyretin in patients with wild-type ATTR-CM or the pathogenic variant ATTRv-CM.
November 04, 2025
Catch up with groundbreaking FDA decisions, exciting new GLP-1 news, and more.
October 21, 2025
A recent study from Duke University spotlighted papSCAR’s substantial association with both cardiovascular mortality and arrhythmia.
October 17, 2025
Witteles highlights the uniform improvement after the tafamidis and vutrisiran arms were both moved to the same vutrisiran dose.
October 15, 2025
An exploratory analysis of the ATTRibute-CM trial spotlighted acoramidis’s superior efficacy in lowering CVD-related risks versus placebo.
October 13, 2025
Desai details recent advancements in medicine and invasive treatments while reminding clinicians of what can still be done to protect patients.
